Catalyst Event
Medtronic PLC (MDT) · Other
From KEDI U.S. Humanoid Robot Index (KUHMRB)
4/29/2026, 12:00:00 AM
Medtronic received U.S. Food and Drug Administration (FDA) approval for the Mosaic Neo mitral valve, its next-generation mitral bioprosthesis, on April 29, 2026.
Korean Translation
메드트로닉은 2026년 4월 29일 차세대 승모판막 생체 인공판막인 Mosaic Neo 승모판막에 대해 미국 식품의약국(FDA)의 승인을 받았음.
Related Recent Events
Honeywell International Inc (HON) · Trading Issue
Honeywell Aerospace spin-off is scheduled to be completed on June 29, 2026, marking the final step in the company's portfolio transformation. The new company will trade under the ticker 'HONA'. This event is scheduled.
6/29/2026, 12:00:00 AM
Honeywell International Inc (HON) · Other
A quarterly dividend of $1.19 per share is scheduled to be paid on June 5, 2026, to shareholders of record as of May 17, 2026. This event is scheduled.
6/5/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. This event is expected to have a medium impact as earnings reports typically drive significant price volatility scheduled.
6/3/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA is scheduled to announce its financial results for the first quarter of fiscal year 2027, which ended on April 26, 2026, after market close on May 20, 2026. High importance is estimated as earnings reports typically trigger significant price movement, scheduled.
5/20/2026, 12:00:00 AM
Zebra Technologies Corp (ZBRA) · Earnings Release
First quarter 2026 financial results are scheduled to be released before the market opens on May 12, 2026; Medium importance estimated as earnings releases typically cause significant price volatility scheduled.
5/12/2026, 12:00:00 AM
Microchip Technology Inc (MCHP) · Earnings Release
Microchip's Q4 and full fiscal year 2026 financial results conference call is scheduled for May 7, 2026. Analysts forecast revenue of approximately $1.26 billion and an adjusted EPS of $0.50. The market has priced in a potential post-earnings price move of over 11%, justifying the high importance scheduled.
5/7/2026, 12:00:00 AM